Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Using structure-guided design, several cell based assays, and microdosed positron emission tomography (PET) imaging, we identified a series of highly potent, selective, and brain-penetrant oxazole-4-carboxamide-based inhibitors of glycogen synthase kinase-3 (GSK-3). An isotopologue of our first-generation lead, [ 3 H]PF-367, demonstrates selective and specific target engagement in vitro, irrespective of the activation state. We discovered substantial ubiquitous GSK-3-specific radioligand binding in Tg2576 Alzheimer’s disease (AD), suggesting application for these compounds in AD diagnosis and identified [ 11 C]OCM-44 as our lead GSK-3 radiotracer, with optimized brain uptake by PET imaging in nonhuman primates. GSK-3β-isozyme selectivity was assessed to reveal OCM-51, the most potent (IC 50 = 0.030 nM) and selective (>10-fold GSK-3β/GSK-3α) GSK-3β inhibitor known to date. Inhibition of CRMP2 T514 and tau phosphorylation, as well as favorable therapeutic window against WNT/β-catenin signaling activation, was observed in cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the selective GSK3β inhibitor OCM-51 (36) could achieve a beneficial balance between reducing tau phosphorylation and preventing overactivation of the β-catenin signaling pathway at appropriate doses.499”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [499]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Cohen, P., & Frame, S. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096075 · Cited by 1,478
Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation
Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M.-S., Jin, O., & Woodgett, J. R. (2000) · Nature · doi:10.1038/35017574 · Cited by 1,393
Molecular cloning and expression of glycogen synthase kinase‐3/factor A.
Woodgett, J. R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07419.x · Cited by 1,362
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C. A., Lee, V. M.-Y., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,196
The GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191
Blalock, E. M., Geddes, J. W., Chen, K. C., Porter, N. M., Markesbery, W. R., & Landfield, P. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308512100 · Cited by 1,025
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Recent Advances in Pyrimidine-Based Drugs
Nammalwar, B., & Bunce, R. A. (2024) · Pharmaceuticals · doi:10.3390/ph17010104 · Cited by 192
Premise and peril of Wnt signaling activation through GSK-3β inhibition
Law, S. M., & Zheng, J. (2022) · iScience · doi:10.1016/j.isci.2022.104159 · Cited by 88
“Indeed, even the most state-of-the-art GSK-3b inhibitors still inhibit a few other kinases at higher concentrations (Bernard-Gauthier et al., 2019).”
Advances toward precision medicine for bipolar disorder: mechanisms & molecules
Haggarty, S. J., Karmacharya, R., & Perlis, R. H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0831-4 · Cited by 114
Self-citationChen, Z., Haider, A., Chen, J., Xiao, Z., Gobbi, L. B., Honer, M., Grether, U., Arnold, S. E., Josephson, L., & Liang, S. H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01571 · Cited by 72
Self-citation
Metadata
- Authors
- Bernard-Gauthier, V., Mossine, A. V., Knight, A., Patnaik, D., Zhao, W.-N., Cheng, C., Krishnan, H. S., Xuan, L. L., Chindavong, P. S., Reis, S. A., Chen, J. M., Shao, X., Stauff, J., Arteaga, J., Sherman, P., Salem, N., Bonsall, D., Amaral, B., Varlow, C., Wells, L., Martarello, L., Patel, S., Liang, S. H., Kurumbail, R. G., Haggarty, S. J., Scott, P. J. H., & Vasdev, N.
- Affiliations
- Azrieli Centre for Neuro-Radiochemistry, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario M5T 1R8, Canada
- University of Michigan (US)
- Centre for Addiction and Mental Health (CA)
- Harvard University (US)
- Pfizer (United States) (US)
- Biogen (United States) (US)
- Invicro (United Kingdom) (GB)
- Eisai (United States) (US)
- Corresponding author
- Vasdev, Neil
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-09-19
- Volume
- 62
- Issue
- 21
- Pages
- 9600-9617
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- PMC
- PMC6883410
- OpenAlex
- W2974123792
- Cited by
- 49
- References
- 51
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 7 · 2023: 10 · 2022: 6 · 2021: 10 · 2020: 3
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Massachusetts General Hospital
- Canada Research Chairs
- National Institute on Aging (R01AG054473)
- Azrieli Foundation
- Rainwater Charitable Foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- GSK-3β inhibition, structure-based drug design, PET radiotracer, brain penetration, Alzheimer's disease imaging, tau phosphorylation, CRMP2, Wnt/β-catenin signaling, microdosing, non-human primates
- MeSH terms
- Glycogen Synthase Kinase 3 beta, Animals, Blood-Brain Barrier, Brain, Humans, Models, Molecular, Oxazoles, Triazoles, Catalytic Domain, Protein Kinase Inhibitors, Positron-Emission Tomography, Mice, Drug Discovery, HEK293 Cells, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery. https://app.cochat.ai/papers/10.1021/acs.jmedchem.9b01030
- The paper
- Bernard-Gauthier, V., Mossine, A. V., Knight, A., Patnaik, D., Zhao, W.-N., Cheng, C., Krishnan, H. S., Xuan, L. L., Chindavong, P. S., Reis, S. A., Chen, J. M., Shao, X., Stauff, J., Arteaga, J., Sherman, P., Salem, N., Bonsall, D., Amaral, B., Varlow, C., . . . Vasdev, N. (2019). Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.9b01030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.